[Clinical studies on 9,3"-diacetylmidecamycin in respiratory tract infections in pediatric field (author's transl)].
Clinical studies on 9,3"-diacetylmidecamycin (MOM) was carried out in 31 patients with respiratory tract infections (acute pharyngitis 6, acute purulent tonsillitis 5, scarlet fever 1, acute bronchitis 6, pneumonia 13 cases), in dose of 12 approximately 34 mg/kg divided 3 per day for 3 approximately 19 days. The overally efficacy rate was 74.2%. As to adverse reaction, exanthema and diarrhea with abdominal pain were observed in each 1 patient. Eosinophilia and elevation of serum GPT were noted in each 1 patient.
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007223:Infant; D007933:Leucomycins / Q000627:therapeutic use*; D008297:Male; D015644:Miocamycin; D012141:Respiratory Tract Infections / Q000188:drug therapy*
D007933:Leucomycins; D015644:Miocamycin